ProCE Banner Activity

FLT3/Axl Inhibitor Gilteritinib (ASP2215) Safe and Active in Relapsed or Refractory AML

Slideset Download
Conference Coverage
Doses of gilteritinib ≥ 80 mg showed an ORR of 58% in patients with relapsed/refractory AML and the FLT3 mutation.

Released: June 05, 2015

Expiration: June 03, 2016

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Celgene

Genentech BioOncology

Incyte

Novartis Pharmaceuticals Corporation